4.37
-0.91%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About HLS Therapeutics
Its shares trade on Toronto Stock Exchange under the ticker HLS.TO. It has been listed since 17 March 1980. In the fiscal year to 31 December 2025, it reported revenue of $56.5m and a net loss of $12.6m. At that date it held total assets of $137.3m and shareholders' equity of $61.6m.
HLS Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Etobicoke, Ontario. The firm acquires and distributes commercial stage and branded pharmaceutical drugs for the North American markets. The firm focuses mainly on treatment products for the central nervous system and cardiovascular specialties in Canada. Its product pipeline includes clozaril, for the treatment of schizophrenia disorders; absorica, for treatment of skin disease, such as acne; vascepa, for the treatment of hypertriglyceridemia, and trinomial for cardiovascular risk reduction. Apart from its operation in a number of regions in Canada, such as Toronto, Ontario, and Montreal, the Company also operates in the United States.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 17 Mar 1980
- Employees
- 52
- Website
- hlstherapeutics.com ↗
Leadership
Pay as last reported
- Mr. John WelbornIndependent Chairman of the Board$165,000
- Mr. Craig MillianChief Executive Officer, Director, since 2023$1.3m
- Mr. John HannaChief Financial Officer, Director, since 2023$598,245
- Mr. Ryan LennoxSenior Vice President - Legal, HR and Compliance, Corporate Secretary$475,233
- Mr. David SpenceVice President, Corporate Controller
- Ms. Patricia PerryVice President - Human Resources
- Mr. Jason GrossVice President - Scientific Affairs$340,158
- Ms. Dawn EdinboroVice President, General Manager of Heritage Life Sciences (Barbados), Inc
- Mr. Brian WalshChief Commercial Officer$618,405
- Ms. Norma BeauchampIndependent Director$110,476
- Dr. Kyle DempseyIndependent Director$112,976
- Ms. Christine ElliottIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 24
- Environment
- 27
- Social
- 13
- Governance
- 31
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong market presence: HLS Therapeutics Inc has established a strong presence in the pharmaceutical industry, allowing them to leverage their brand and reputation.
- Diversified product portfolio: The company offers a range of pharmaceutical products, providing them with multiple revenue streams and reducing dependence on a single product.
- Experienced management team: HLS Therapeutics Inc is led by a highly experienced management team with deep industry knowledge and expertise.
Weaknesses
- Limited geographic presence: The company primarily operates in specific regions, limiting its potential market reach and growth opportunities in new markets.
- Dependence on external suppliers: HLS Therapeutics Inc relies on external suppliers for the procurement of raw materials, which exposes them to supply chain risks and potential disruptions.
- Relatively small market share: Compared to some of its competitors, HLS Therapeutics Inc holds a relatively smaller market share, which may pose challenges in terms of market penetration and competition.
Opportunities
- Emerging markets: Expanding into emerging markets with a growing elderly population presents HLS Therapeutics Inc with opportunities to tap into new customer segments and increase sales.
- Strategic partnerships and acquisitions: Collaborating with strategic partners or acquiring smaller pharmaceutical companies can provide HLS Therapeutics Inc with access to new technologies, products, and markets.
- R&D investments: Investing in research and development can enable HLS Therapeutics Inc to develop innovative drugs and treatments, potentially leading to a competitive advantage.
Threats
- Regulatory challenges: Increasing regulations in the pharmaceutical industry may impose additional compliance requirements and impact the company's operations and profitability.
- Intense competition: HLS Therapeutics Inc operates in a highly competitive market with numerous established pharmaceutical companies, posing threats to market share and pricing pressures.
- Economic uncertainties: Fluctuations in the economy, including changes in healthcare policies and reimbursement systems, can influence the demand for pharmaceutical products and impact the company's financial performance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.